Min Luo1, Dongxiang Shen2, Wei Wang3, Jiang Xian4. 1. Department of Obstetrics and Gynecology, Guangzhou General Hospital of Guangzhou Military Command 111 Liuhua Road, Guangzhou 510010, China. 2. Health Cadre Training Center, Guangzhou Military Command 111 Liuhua Road, Guangzhou 510010, China. 3. Department of Pathology, Guangzhou General Hospital of Guangzhou Military Command 111 Liuhua Road, Guangzhou 510010, China. 4. Departemnt of Medical Research, Guangzhou General Hospital of Guangzhou Military Command 111 Liuhua Road, Guangzhou 510010, China.
Abstract
BACKGROUND: microRNA-26b (miR-26b) is reported to be downregulated in many human malignancies and function as a tumor suppressor. However, the roles of miR-26b expression in cervical cancer progression are unclear. The aim of this study was to investigate the clinicopathological or prognostic significance of miR-26b in human cervical cancer. METHODS: A cohort of 88 paired of cervical cancer and the adjacent normal cervical epithelial tissues were collected. Quantitative RT-PCR (qRT-PCR) assay was used to detect the expression of miR-26b and its correlations with clinicopathological factors were statistically analyzed. Finally, the survival was assessed by the Kaplan-Meier method and proportional hazards model. RESULTS: The expression level of miR-26b in cervical cancer tissues was significantly lower than that in the adjacent normal cervical tissues (P<0.001). Reduced miR-26b was observed to be significantly correlated with advanced FIGO stage, higher incidence of lymph node metastasis and recurrence of cervical cancer patients (P=0.002, 0.036 and 0.029, respectively). In addition, patients with low-miR-26b expression showed poorer recurrence-free survival (RFS) and overall survival (OS) than those with high-miR-26b expression (P=0.0043 and 0.0015, respectively). Furthermore, multivariate analyses demonstrated that low miR-26b expression was an independent prognostic factor for predicting the 5-year RFS and OS of cervical cancer patients (P=0.013 and 0.007, respectively). CONCLUSION: Our results showed that reduced miR-26b was correlated with tumor development and poor prognosis in human cervical cancer. The status of miR-26b expression may be a potential prognostic biomarker for cervical cancer patients.
BACKGROUND:microRNA-26b (miR-26b) is reported to be downregulated in many humanmalignancies and function as a tumor suppressor. However, the roles of miR-26b expression in cervical cancer progression are unclear. The aim of this study was to investigate the clinicopathological or prognostic significance of miR-26b in humancervical cancer. METHODS: A cohort of 88 paired of cervical cancer and the adjacent normal cervical epithelial tissues were collected. Quantitative RT-PCR (qRT-PCR) assay was used to detect the expression of miR-26b and its correlations with clinicopathological factors were statistically analyzed. Finally, the survival was assessed by the Kaplan-Meier method and proportional hazards model. RESULTS: The expression level of miR-26b in cervical cancer tissues was significantly lower than that in the adjacent normal cervical tissues (P<0.001). Reduced miR-26b was observed to be significantly correlated with advanced FIGO stage, higher incidence of lymph node metastasis and recurrence of cervical cancerpatients (P=0.002, 0.036 and 0.029, respectively). In addition, patients with low-miR-26b expression showed poorer recurrence-free survival (RFS) and overall survival (OS) than those with high-miR-26b expression (P=0.0043 and 0.0015, respectively). Furthermore, multivariate analyses demonstrated that low miR-26b expression was an independent prognostic factor for predicting the 5-year RFS and OS of cervical cancerpatients (P=0.013 and 0.007, respectively). CONCLUSION: Our results showed that reduced miR-26b was correlated with tumor development and poor prognosis in humancervical cancer. The status of miR-26b expression may be a potential prognostic biomarker for cervical cancerpatients.
Authors: Muralidharan Jayaraman; Rangasudhagar Radhakrishnan; Cara A Mathews; Mingda Yan; Sanam Husain; Katherine M Moxley; Yong Sang Song; Danny N Dhanasekaran Journal: Genes Cancer Date: 2017-05
Authors: Angelica Judith Granados-López; José Luis Ruiz-Carrillo; Luis Steven Servín-González; José Luis Martínez-Rodríguez; Claudia Araceli Reyes-Estrada; Rosalinda Gutiérrez-Hernández; Jesús Adrián López Journal: Int J Mol Sci Date: 2017-02-14 Impact factor: 5.923